Literature DB >> 19255346

Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms.

Raffaella Lombardi1, Gabriela Rodriguez, Suet Nee Chen, Crystal M Ripplinger, Wenwen Li, Junjie Chen, James T Willerson, Sandro Betocchi, Samuel A Wickline, Igor R Efimov, Ali J Marian.   

Abstract

BACKGROUND: Cardiac hypertrophy, the clinical hallmark of hypertrophic cardiomyopathy (HCM), is a major determinant of morbidity and mortality not only in HCM but also in a number of cardiovascular diseases. There is no effective therapy for HCM and generally for cardiac hypertrophy. Myocardial oxidative stress and thiol-sensitive signaling molecules are implicated in pathogenesis of hypertrophy and fibrosis. We posit that treatment with N-acetylcysteine, a precursor of glutathione, the largest intracellular thiol pool against oxidative stress, could reverse cardiac hypertrophy and fibrosis in HCM. METHODS AND
RESULTS: We treated 2-year-old beta-myosin heavy-chain Q403 transgenic rabbits with established cardiac hypertrophy and preserved systolic function with N-acetylcysteine or a placebo for 12 months (n=10 per group). Transgenic rabbits in the placebo group had cardiac hypertrophy, fibrosis, systolic dysfunction, increased oxidized to total glutathione ratio, higher levels of activated thiol-sensitive active protein kinase G, dephosphorylated nuclear factor of activated T cells (NFATc1) and phospho-p38, and reduced levels of glutathiolated cardiac alpha-actin. Treatment with N-acetylcysteine restored oxidized to total glutathione ratio, normalized levels of glutathiolated cardiac alpha-actin, reversed cardiac and myocyte hypertrophy and interstitial fibrosis, reduced the propensity for ventricular arrhythmias, prevented cardiac dysfunction, restored myocardial levels of active protein kinase G, and dephosphorylated NFATc1 and phospho-p38.
CONCLUSIONS: Treatment with N-acetylcysteine, a safe prodrug against oxidation, reversed established cardiac phenotype in a transgenic rabbit model of human HCM. Because there is no effective pharmacological therapy for HCM and given that hypertrophy, fibrosis, and cardiac dysfunction are common and major predictors of clinical outcomes, the findings could have implications in various cardiovascular disorders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19255346      PMCID: PMC2773801          DOI: 10.1161/CIRCULATIONAHA.108.790501

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  38 in total

1.  N-acetylcysteine replenishes glutathione in HIV infection.

Authors:  S C De Rosa; M D Zaretsky; J G Dubs; M Roederer; M Anderson; A Green; D Mitra; N Watanabe; H Nakamura; I Tjioe; S C Deresinski; W A Moore; S W Ela; D Parks; L A Herzenberg; L A Herzenberg
Journal:  Eur J Clin Invest       Date:  2000-10       Impact factor: 4.686

2.  Tissue Doppler imaging consistently detects myocardial contraction and relaxation abnormalities, irrespective of cardiac hypertrophy, in a transgenic rabbit model of human hypertrophic cardiomyopathy.

Authors:  S F Nagueh; H A Kopelen; D S Lim; W A Zoghbi; M A Quiñones; R Roberts; A J Marian
Journal:  Circulation       Date:  2000-09-19       Impact factor: 29.690

3.  Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia.

Authors:  Y Hoshikawa; S Ono; S Suzuki; T Tanita; M Chida; C Song; M Noda; T Tabata; N F Voelkel; S Fujimura
Journal:  J Appl Physiol (1985)       Date:  2001-04

Review 4.  Hypertrophic cardiomyopathy: a systematic review.

Authors:  Barry J Maron
Journal:  JAMA       Date:  2002-03-13       Impact factor: 56.272

Review 5.  New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment.

Authors:  Michael R Zile; Dirk L Brutsaert
Journal:  Circulation       Date:  2002-03-26       Impact factor: 29.690

6.  Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy.

Authors:  R Patel; S F Nagueh; N Tsybouleva; M Abdellatif; S Lutucuta; H A Kopelen; M A Quinones; W A Zoghbi; M L Entman; R Roberts; A J Marian
Journal:  Circulation       Date:  2001-07-17       Impact factor: 29.690

7.  A transgenic rabbit model for human hypertrophic cardiomyopathy.

Authors:  A J Marian; Y Wu; D S Lim; M McCluggage; K Youker; Q T Yu; R Brugada; F DeMayo; M Quinones; R Roberts
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

Review 8.  Genetic determinants of cardiac hypertrophy.

Authors:  Ali J Marian
Journal:  Curr Opin Cardiol       Date:  2008-05       Impact factor: 2.161

9.  Evolution of expression of cardiac phenotypes over a 4-year period in the beta-myosin heavy chain-Q403 transgenic rabbit model of human hypertrophic cardiomyopathy.

Authors:  Sherif F Nagueh; Suetnee Chen; Rajnikant Patel; Natalia Tsybouleva; Silvia Lutucuta; Helen A Kopelen; William A Zoghbi; Miguel A Quiñones; Robert Roberts; A J Marian
Journal:  J Mol Cell Cardiol       Date:  2004-05       Impact factor: 5.000

10.  Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy.

Authors:  P Spirito; P Bellone; K M Harris; P Bernabo; P Bruzzi; B J Maron
Journal:  N Engl J Med       Date:  2000-06-15       Impact factor: 91.245

View more
  49 in total

Review 1.  Nuclear cardiac imaging in hypertrophic cardiomyopathy.

Authors:  Jamshid Shirani; Vasken Dilsizian
Journal:  J Nucl Cardiol       Date:  2011-02       Impact factor: 5.952

2.  Update on hypertrophic cardiomyopathy.

Authors:  Ali J Marian
Journal:  Tex Heart Inst J       Date:  2010

Review 3.  Role of animal models in HCM research.

Authors:  Rhian Shephard; Christopher Semsarian
Journal:  J Cardiovasc Transl Res       Date:  2009-08-07       Impact factor: 4.132

Review 4.  Hypertrophic cardiomyopathy: from genetics to treatment.

Authors:  Ali J Marian
Journal:  Eur J Clin Invest       Date:  2010-04       Impact factor: 4.686

Review 5.  Contemporary treatment of hypertrophic cardiomyopathy.

Authors:  Ali J Marian
Journal:  Tex Heart Inst J       Date:  2009

Review 6.  Protective transcriptional mechanisms in cardiomyocytes and cardiac fibroblasts.

Authors:  Cameron S Brand; Janet K Lighthouse; Michael A Trembley
Journal:  J Mol Cell Cardiol       Date:  2019-04-28       Impact factor: 5.000

Review 7.  Therapeutic Strategies Targeting Inherited Cardiomyopathies.

Authors:  Kenneth Varian; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2017-08

8.  Desensitization of myofilaments to Ca2+ as a therapeutic target for hypertrophic cardiomyopathy with mutations in thin filament proteins.

Authors:  Marco L Alves; Fernando A L Dias; Robert D Gaffin; Jillian N Simon; Eric M Montminy; Brandon J Biesiadecki; Aaron C Hinken; Chad M Warren; Megan S Utter; Robert T Davis; Sadayappan Sakthivel; Jeffrey Robbins; David F Wieczorek; R John Solaro; Beata M Wolska
Journal:  Circ Cardiovasc Genet       Date:  2014-02-28

9.  Hypertrophy Regression With N-Acetylcysteine in Hypertrophic Cardiomyopathy (HALT-HCM): A Randomized, Placebo-Controlled, Double-Blind Pilot Study.

Authors:  Ali J Marian; Yanli Tan; Lili Li; Jeffrey Chang; Petros Syrris; Manouchehr Hessabi; Mohammad H Rahbar; James T Willerson; Benjamin Y Cheong; Chia-Ying Liu; Neal S Kleiman; David A Bluemke; Sherif F Nagueh
Journal:  Circ Res       Date:  2018-03-14       Impact factor: 17.367

10.  Deficient cMyBP-C protein expression during cardiomyocyte differentiation underlies human hypertrophic cardiomyopathy cellular phenotypes in disease specific human ES cell derived cardiomyocytes.

Authors:  Andre Monteiro da Rocha; Guadalupe Guerrero-Serna; Adam Helms; Carly Luzod; Sergey Mironov; Mark Russell; José Jalife; Sharlene M Day; Gary D Smith; Todd J Herron
Journal:  J Mol Cell Cardiol       Date:  2016-09-10       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.